US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

HORIZON KINETICS MEDICAL ETF

35.06

0.0000

Volume:65

Turnover:2.28K

Market Cap:16.48M

PE:- -

High:35.06

Open:35.06

Low:35.06

Close:35.06

52wk High:37.90

52wk Low:28.87

Shares:469.95K

Float Shares:469.95K

Volume Ratio:0.04

T/O Rate:0.01%

Dividend:0.41

Dividend Rate:1.17%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Johnson & Johnson Receives Ce Marking for Acuvue Oasys Max Reusable Contact Lenses

THOMSON REUTERS

CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder

Alkermes Announces Launch of 9TH Annual Alkermes Pathways Research Awards® Program

THOMSON REUTERS

HSBC Adjusts Price Target on Eli Lilly and Co. to $940 From $850, Keeps Reduce Rating

MT Newswires Live

Market Wrap September 10: Innovation Drug Shares Dip Amid Clinical Setback, Bank Stocks Post Modest Gains

Medmix Teams with Xeris to Power Precise Delivery of New Hypothyroidism Therapy

Novartis India Hits Record High After Recent Acquisition, Distribution Deal

Tellgen's Subsidiary Device Registration Application Accepted by Regulator

Northeast Securities: Innovative Drug BD and Commercialization Deliver Consistent Wins, CXO Exceeds Projections, Traditional Segments Approach Turnaround

AI-Driven Drug Candidate From INSILICO Reaches Major Milestone As Phase 3 Trial Enrolls First Patients

LIFETECH SCI's LantvalTM Aortic Valve Replacement System Clears NMPA Fast-Track Review for Innovative Devices

Novartis AG Falls Wednesday, Outperforms Market

Dyne Therapeutics Myotonic Dystrophy Approach Remains Differentiated, RBC Says

MT Newswires Live

Novartis Shouldn't Rush to Cover Upcoming Patent Expirations

Tyra Biosciences Stock Plunges 22% as Bladder Cancer Pill Fails to Impress

Abbvie Exec Says Strong Balance Sheet and Long Growth Runway Allow Company to Consider Both Early- and Late-Stage Business Development Opportunities - Conf Call

THOMSON REUTERS

Abbvie Exec Says Expects Approval of Subcutaneous Crohn's Disease Treatment in Q4 - Conf Call

THOMSON REUTERS

Henlius CEO Zhu Jun: Systematic Globalization Aims for Long-Term Gains, Innovative Drug Revenue Set to Surpass Biosimilars by 2030

IMUNON Announces Full Agenda and Speaker Lineup Ahead of 2026 R&D Day Highlighting IMNN-001 Clinical Progress

ProQR Therapeutics doses first participant in AX-0811 clinical trial

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnexa.com/stock/MEDX/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MEDX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MEDX\",,,,,undefined,":{"symbol":"MEDX","market":"US","secType":"STK","nameCN":"HORIZON KINETICS MEDICAL ETF","latestPrice":35.0604,"timestamp":1789142697375,"preClose":35.0604,"halted":0,"volume":65,"delay":0,"changeRate":0,"floatShares":469946,"shares":469946,"eps":0,"marketStatus":"Trading","change":0,"latestTime":"09-11 13:17:52 EDT","open":35.0604,"high":35.0604,"low":35.0604,"amount":2282.8232700000003,"amplitude":0,"askPrice":35.16,"askSize":700,"bidPrice":34.97,"bidSize":500,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1789156800000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":35.0604,"sharesOutstanding":569946,"nav":35.21,"aum":16546798.66,"dividendRate":0.0117,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":35.2396,"preClose":35.0604,"latestTime":"16:10 EDT","volume":6,"amount":210.2016,"timestamp":1789071007727,"change":0.1792,"changeRate":0.005111,"amplitude":0},"volumeRatio":0.042971},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MEDX\",,,,,undefined,":{"symbol":"MEDX","floatShares":469946,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.042971,"shares":469946,"dividePrice":0.4102,"high":35.0604,"amplitude":0,"preClose":35.0604,"low":35.0604,"week52Low":28.8652,"pbRate":"--","week52High":37.9,"institutionHeld":0,"latestPrice":35.0604,"committee":-0.166667,"eps":0,"divideRate":0.0117,"volume":65,"delay":0,"ttmEps":0,"open":35.0604,"prevYearClose":33.2024,"prevWeekClose":36.6906,"prevMonthClose":36.417,"prevQuarterClose":36.7138,"fiveDayClose":37.0834,"twentyDayClose":35.9599,"sixtyDayClose":34.1895},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MEDX\",params:#limit:5,,,undefined,":[{"date":"2025-12-23","symbol":"MEDX","amount":0.4088,"announcedDate":"2025-12-22","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-23","defaultRemindTime":1766500200000,"name":"HORIZON KINETICS MEDICAL ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-24","payableDate":"2025-12-23","currency":"USD","dateTimestamp":1766466000000,"payDate":"2025-12-24"},{"date":"2024-12-24","symbol":"MEDX","amount":0.502335,"announcedDate":"2024-12-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-24","defaultRemindTime":1735050600000,"name":"HORIZON KINETICS MEDICAL ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-26","payableDate":"2024-12-24","currency":"USD","dateTimestamp":1735016400000,"payDate":"2024-12-26"},{"date":"2023-12-27","symbol":"MEDX","amount":1.379798,"announcedDate":"2023-12-26","type":"dividend","market":"US","newRecordDate":"2023-12-28","defaultRemindTime":1703687400000,"name":"HORIZON KINETICS MEDICAL ETF","recordDate":"2023-12-29","payableDate":"2023-12-28","currency":"USD","dateTimestamp":1703653200000,"payDate":"2023-12-29"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MEDX\",market:\"US\",,,undefined,":[{"executeDate":"2023-12-27","recordDate":"2023-12-28","paymentDate":"2023-12-29","value":1.379798,"currency":"USD"},{"executeDate":"2024-12-24","recordDate":"2024-12-24","paymentDate":"2024-12-26","value":0.502335,"currency":"USD"},{"executeDate":"2025-12-23","recordDate":"2025-12-23","paymentDate":"2025-12-24","value":0.4088,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MEDX\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MEDX\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666598631","title":"Johnson & Johnson Receives Ce Marking for Acuvue Oasys Max Reusable Contact Lenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2666598631","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666598631?lang=en_us&edition=fundamental","pubTime":"2026-09-10 19:45","pubTimestamp":1789040700,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nTUA26VGSH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00B4R5TH58.HKD","GDOC","LU1043141396.HKD","IE00BLSP4239.USD","LU0320765646.SGD","LU1032955483.USD","MEDX","BK4559","IE00BFXG1179.USD","IYH","JNJ","LU0432979614.USD","BMED","LU0058720904.USD","IE00BBT3K403.USD","LU1506573853.SGD","JDOC","LU0466842654.USD","LU1261432733.SGD","IE000WAW04H5.SGD","IE00BJT1NW94.SGD","LU2129689605.HKD","FTXH","LU2592432038.USD","IHE","FHLC","LU1894683264.USD","BK4550","IXJ","XLV","RXL","LU1935042991.SGD","LU2089984988.USD","LU1057294990.SGD","LU2602419157.SGD","LU2023250330.USD","IE00BVYPNW00.USD","LU2487616109.SGD","SGXZ57979304.SGD","VHT","LU1280957306.USD","LU2750360641.GBP","TRUH","LU1291159041.SGD","PJP","LU1032466523.USD","BK4533","LU0345770308.USD","LU1074936037.SGD","BK4504"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666598627","title":"CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder","url":"https://stock-news.laohu8.com/highlight/detail?id=2666598627","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666598627?lang=en_us&edition=fundamental","pubTime":"2026-09-10 19:33","pubTimestamp":1789039980,"startTime":"0","endTime":"0","summary":"Authorization from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) builds on CAMP4’s recent clearances to initiate first-in-human studies for CMP-002 in Australia and Argentina Com","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/10/3359400/0/en/camp4-therapeutics-receives-authorization-in-the-united-kingdom-for-phase-1-2-human-clinical-trial-of-cmp-002-in-patients-with-syngap1-related-disorder.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4200","BK4139","CMP","NVIB","BK4007","MEDX","UBCP","BK4211","LENZ","ASO","BK4561","HYLG","IDNA","BK4168","GDOC","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666567022","title":"Alkermes Announces Launch of 9TH Annual Alkermes Pathways Research Awards® Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2666567022","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666567022?lang=en_us&edition=fundamental","pubTime":"2026-09-10 19:00","pubTimestamp":1789038000,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nTUA8WKBZB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PSCH","BK4139","MEDX","IBRN","ALKS","FBT","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666561456","title":"HSBC Adjusts Price Target on Eli Lilly and Co. to $940 From $850, Keeps Reduce Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2666561456","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666561456?lang=en_us&edition=fundamental","pubTime":"2026-09-10 17:34","pubTimestamp":1789032857,"startTime":"0","endTime":"0","summary":"Eli Lilly and Company (LLY) has an average rating of overweight and mean price target of $1,352.49, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["FTXH","LLY","LU0289739699.SGD","LU1548497426.USD","LU0006306889.USD","WDNA","LU2896262040.SGD","LU1291159041.SGD","LU2552382132.HKD","LU2491049909.HKD","BK4599","SGXZ99366536.SGD","LU2063271972.USD","IYH","LU2324357040.USD","LU0097036916.USD","LU2211815571.USD","LU0466842654.USD","GB00BDT5M118.USD","LU2468319806.SGD","LU1551013425.SGD","LU2360106947.USD","BK4585","GDOC","LU2471134879.HKD","TRUH","LU2237443465.HKD","LLYX","LU0323591593.USD","LU0820561909.HKD","LU2237443549.SGD","LU2168564065.EUR","LU2361044865.SGD","LU1868836591.USD","LU0225283273.USD","IE00BJJMRZ35.SGD","LU1280957306.USD","LU2602419157.SGD","SG9999014880.SGD","LU2750360997.AUD","BK4534","IE0005OL40V9.USD","LU2168564149.EUR","LU2112291526.USD","LU2750360641.GBP","OZEM","LU0823416689.USD","LU1023059063.AUD","LU2746668461.USD","IE00BJT1NW94.SGD","LU2108987350.USD","LU2756315664.SGD","TMED","SG9999018857.SGD","SG9999015978.USD","IE00BK4W5L77.USD","LU0353189763.USD","LU2756315318.SGD","LU2168563687.JPY","LU2471134523.USD","IHE","IE00BWXC8680.SGD","LU1323610961.USD","LU0385154629.USD","LU1057294990.SGD","SG9999018865.SGD","VHT","LU0354030438.USD","LU0094547139.USD","PJP","IE00BFSS8Q28.SGD","AGNG","LU1814569148.SGD","IE00BN29S564.USD","SGXZ51526630.SGD","RXL","LU1093756325.SGD","IE0002141913.USD","LU0234572021.USD","ILDR","LU1712237335.SGD","LU1629891620.HKD","LU0256863811.USD","LU1127390331.HKD","LU0820562030.AUD","LU0882574055.USD","LU1061106388.HKD","IE0004445015.USD","LU0133085943.USD","LU0109391861.USD","LU2023250330.USD","SG9999001176.USD","LU2236285917.USD","LU0079474960.USD","LU0640476718.USD","LU0096364046.USD","LU2168564495.EUR","IE00B2B36J28.USD","LU0820561818.USD","THNR","IE00B4R5TH58.HKD","LU1868837300.USD","LU2023251221.USD","SG9999014898.SGD","LU2552382215.SGD","LU1804176565.USD","LU1979441026.SGD","LU1093756168.USD","IE0004445239.USD","LU2461242641.AUD","LU2456880835.USD","LU1232071149.USD","LU0787776722.HKD","LU0238689110.USD","LU0122379950.USD","BK4533","LU0708995401.HKD","LU1988902786.USD","LU2417539215.USD","IE00B4JS1V06.HKD","IE00B775H168.HKD","LU0964807845.USD","LU1974910355.USD","XLV","LU1064131342.USD","IE0001KFT4U8.USD","LU1366192091.USD","LU0203201768.USD","SG9999001176.SGD","IE00BFSS7M15.SGD","IXJ","SG9999015986.USD","LU1623119135.USD","LU2237443978.SGD","IE00BKPKM429.USD","LU1551013342.USD","SGXZ31699556.SGD","LU0174119429.USD","LU2168564222.USD","IE00B1BXHZ80.USD","LU0256863902.USD","LU0432979614.USD","LU2111349929.HKD","LU2237443382.USD","ELIS","LU0786609619.USD","IE0009355771.USD","LU0345770993.USD","LU0456855351.SGD","MEDX","LU2237443622.USD","LU2471134952.CNY","LU1267930730.SGD","LLYZ","LU0106261372.USD","LU0672654240.SGD","LU1917777945.USD","LU0471298694.HKD","LU2265009873.SGD","LU2462591350.SGD","LU0471298777.SGD","LU2462157665.USD","LU0882574139.USD","LU2237443895.HKD","LU2357305700.SGD","SG9999014914.USD","LU0203202063.USD","IE00BFTCPJ56.SGD","BK4007","LU0198837287.USD","SG9999017495.SGD","BK4516","LU0345770308.USD","LU2089283258.USD","BK4588","LU0114720955.EUR","LU0689472784.USD","LU2087625088.SGD","LLII","LU2023250504.SGD","LU0320765992.SGD","LU2237438978.USD","LU0320765059.SGD","LU0158827781.USD","LU2491050071.SGD","LU0266013472.USD","LU2213496289.HKD","LU0058720904.USD","IE00B1XK9C88.USD","LU1868836914.USD","BK4581","IE00BKDWB100.SGD","IE00BJJMRY28.SGD","LU1989771016.USD","LU2028103732.USD","JDOC","LU0354030511.USD","LU2552382058.USD","SG9999015952.SGD","IE00BK4W5M84.HKD","LU1720051108.HKD","LU0823434583.USD","LU0889565916.HKD","SGXZ81514606.USD","SG9999014906.USD","LU1868836757.USD","IE00B7KXQ091.USD","LU1145028129.USD","LU0316494557.USD","MHIP","LU2361044949.HKD","MEDI","LU0823434740.USD","LU1983299246.USD","LU1720051017.SGD","LU0353189680.USD","LU0683600562.USD","PPH","SG9999015945.SGD","LU0943347566.SGD","IE00BJLML261.HKD","LU2106854487.HKD","LU0158827948.USD","LU2089284900.SGD","LU1069344957.HKD","LU2491050154.USD","LU0417517546.SGD","CANC","LU1691799644.USD","LU2271345857.HKD","SG9999013999.USD","SGXZ57979304.SGD","CURE","LU1035775433.USD","LU2746668974.SGD","LU2264538146.SGD","LU0210536198.USD","LU2089984988.USD","LU2361045086.USD","LU2471134796.USD","FHLC","IE00BJJMRX11.SGD","ELIL","HRTS","LU0061475181.USD","LU0109394709.USD","LU1868837136.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173269814","title":"Market Wrap September 10: Innovation Drug Shares Dip Amid Clinical Setback, Bank Stocks Post Modest Gains","url":"https://stock-news.laohu8.com/highlight/detail?id=1173269814","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173269814?lang=en_us&edition=fundamental","pubTime":"2026-09-10 16:55","pubTimestamp":1789030552,"startTime":"0","endTime":"0","summary":"Hong Kong equities extended their losing streak as escalating Middle East tensions and rising oil prices stoked inflation concerns. A combination of factors, including clinical trial risk events,...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SWP","PY","EQRR","VLUE","VUSV","ROPE","BK4588","159992","ABEQ","BK4585","IBBQ","06978","BK4550","DFLV","BK1161","BK1574","VTV","PRF","FDN","VMAX","LNGR","TALV","BKDV","CGVV","MEDX","SPVM","VALQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666563044","title":"Medmix Teams with Xeris to Power Precise Delivery of New Hypothyroidism Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2666563044","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666563044?lang=en_us&edition=fundamental","pubTime":"2026-09-10 15:32","pubTimestamp":1789025547,"startTime":"0","endTime":"0","summary":"An update from medmix AG ( ($CH:MEDX) ) is now available. Medmix’ Drug Delivery unit Haselmeier has entered a collaboration with Xeris Pharmaceutic...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/medmix-teams-with-xeris-to-power-precise-delivery-of-new-hypothyroidism-therapy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/medmix-teams-with-xeris-to-power-precise-delivery-of-new-hypothyroidism-therapy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666655750","title":"Novartis India Hits Record High After Recent Acquisition, Distribution Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2666655750","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666655750?lang=en_us&edition=fundamental","pubTime":"2026-09-10 13:29","pubTimestamp":1789018142,"startTime":"0","endTime":"0","summary":"BUZZ-Novartis India hits record high after recent acquisition, distribution deal** Pharma co Novartis India'sNOIN.BOshares rise 18% to 2,580 rupees, hitting an all-time high** Stock has gained in six of last seven trading sessions** Gains come after co on Tuesday said it entered into an exclusive promotion and distribution agreement with Novartis Healthcare to market its retina portfolio in India** On Monday, Novartis India said that it would acquire the Minipress brand and related IP from PfizerPFE.Nfor about 12.5 billion rupees ** NOIN holds trailing 12-month PE of 55.26 vs industry median of 23.98","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nL4N4520C5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B4R5TH58.HKD","LU2596442595.SGD","BK4568","SG9999013999.USD","LU0868494617.USD","IE00BLSP4239.USD","BK4599","BK4007","IE0002141913.USD","BK4532","IE0009355771.USD","LU0208291251.USD","LU1883839398.USD","MEDX","SG9999001176.SGD","LU0306806265.USD","LU0058720904.USD","IE00BBT3K403.USD","LU0321505439.SGD","IE00BJT1NW94.SGD","LU0289739699.SGD","LU1066051498.USD","SG9999003800.SGD","LU1894683348.USD","IE00BJJMRZ35.SGD","BK4534","LU1894683264.USD","BK4550","NVS","BK4581","SG9999001176.USD","LU0234572021.USD","LU0306807586.USD","IE00B19Z3B42.SGD","BK4578","IE00B3T34201.USD","LU1057294990.SGD","LU1023059063.AUD","LU0985481810.HKD","IE0002270589.USD","IE00B2B36J28.USD","SG9999002232.USD","LU0321505868.SGD","LU0170899867.USD","SG9999002224.SGD","SGXZ57979304.SGD","LU0225771236.USD","LU0225284248.USD","IE00BFTCPJ56.SGD","SG9999011175.SGD","IE00BLSP4452.SGD","LU0211331839.USD","IE000M9KFDE8.USD","BK4585","IE00B19Z3581.USD","LU0456855351.SGD","LU1066053197.SGD","LU0122379950.USD","PFE","BK4588","BK4533","LU0320765489.SGD","LU0070302665.USD","BK4592","PPH","OZEM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199145560","title":"Tellgen's Subsidiary Device Registration Application Accepted by Regulator","url":"https://stock-news.laohu8.com/highlight/detail?id=1199145560","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199145560?lang=en_us&edition=fundamental","pubTime":"2026-09-10 11:54","pubTimestamp":1789012483,"startTime":"0","endTime":"0","summary":"Tellgen Corporation (SZSE: 300642) has announced that its controlling subsidiary, Shanghai Maishi Biotechnology Co., Ltd., recently had its medical device registration application accepted for review...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0042","LNGR","AGNG","IEIH","BK0239","GDOC","BK0046","BK1583","159883","09996","BK1100","BK1574","MEDX","300642","PTH","RSPH","HART","LGHT","MDEV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192676541","title":"Northeast Securities: Innovative Drug BD and Commercialization Deliver Consistent Wins, CXO Exceeds Projections, Traditional Segments Approach Turnaround","url":"https://stock-news.laohu8.com/highlight/detail?id=1192676541","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192676541?lang=en_us&edition=fundamental","pubTime":"2026-09-10 10:08","pubTimestamp":1789006103,"startTime":"0","endTime":"0","summary":"Investment banking firm Northeast Securities Co.,Ltd. has released a research report indicating that the high prosperity of the overseas innovative drug industry is set to continue, allowing domestic...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0028","MEDX","000686","BK0188","BK1161","BK0183","06978","BK1574","BK0276","LNGR","WX","IBBQ","159992","CXO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103728541","title":"AI-Driven Drug Candidate From INSILICO Reaches Major Milestone As Phase 3 Trial Enrolls First Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=1103728541","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103728541?lang=en_us&edition=fundamental","pubTime":"2026-09-10 08:26","pubTimestamp":1789000007,"startTime":"0","endTime":"0","summary":"INSILICO (03696) has announced that its lead artificial intelligence-powered investigational drug, Rentosertib (also known as ISM001-055/INS018_055), has achieved a significant clinical milestone...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TQQY","CHAT","NEWZ","QQQM","AIFD","TARK","09834","BK4593","02834","AQGX","FWD","PSYK","QQA","OGIG","TQQQ","QTOC","BK1141","03696","LNGR","BK1161","QSWN","MVPS","03086","ARTY","NJUL","DQJN","AGIX","NAPR","QDEC","QMAR","BK1574","AIQU","MEDX","03455","NOCT","07261","161631","IBBJ","VUSE","WPAI","09086","MFIG","AIBU","TECY","SQQQ","MDTX","NJAN","BMED","07568","06978","GPIQ","CPNQ","GK","07266","LCLG","QQQ","PBOT","PSQ","QQQX","07522","159992","KOMP","NBDS","CWC","03034","IBBQ","QLD","QID"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156894230","title":"LIFETECH SCI's LantvalTM Aortic Valve Replacement System Clears NMPA Fast-Track Review for Innovative Devices","url":"https://stock-news.laohu8.com/highlight/detail?id=1156894230","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156894230?lang=en_us&edition=fundamental","pubTime":"2026-09-10 08:08","pubTimestamp":1788998900,"startTime":"0","endTime":"0","summary":"LIFETECH SCI (01302) has announced that it received an official written notice from the National Medical Products Administration (NMPA) on September 9, 2026, confirming that the LantvalTM aortic...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HART","09996","GDOC","AGNG","159883","BK1100","01302","BK1600","LGHT","RSPH","LNGR","IEIH","MDEV","BK1574","BK1583","PTH","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666531005","title":"Novartis AG Falls Wednesday, Outperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2666531005","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666531005?lang=en_us&edition=fundamental","pubTime":"2026-09-10 00:15","pubTimestamp":1788970500,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of Novartis AG  slipped 0.1% to CHF111.66 Wednesday on what proved to be an overall unfavorable trading session for the stock market, with the Swiss Market Index SMI Index  falling 1.8% to 13,804.70.Novartis AG closed CHF21.02 below its 52-week high of CHF132.68, which the company achieved on September 3, 2026.Trading volume was 4,314,570, compared to the 50-day average trading volume of 2,451,167.Data source: Dow Jones Market Data, FactSet","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFTCPJ56.SGD","BK4532","MEDX","BK4578","LU0320765489.SGD","BK4007","IE0002141913.USD","IE0009355771.USD","BK4588","NVS","PPH","BK4585","IE00BJT1NW94.SGD","IE00B2B36J28.USD","LU0070302665.USD","LU0211331839.USD","LU0208291251.USD","IE00B4R5TH58.HKD","IE00BJJMRZ35.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666539005","title":"Dyne Therapeutics Myotonic Dystrophy Approach Remains Differentiated, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2666539005","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666539005?lang=en_us&edition=fundamental","pubTime":"2026-09-09 23:10","pubTimestamp":1788966641,"startTime":"0","endTime":"0","summary":"Dyne Therapeutics  investment thesis remains intact despite a setback for Novartis  in a phase 3 trial for myotonic dystrophy type 1, as differences in drug targeting, payload and clinical strategy could lead to different outcomes, RBC Capital Markets said in a Tuesday note.According to the analysts, Dyne's approach uses an antibody fragment rather than a full-length antibody, an antisense oligonucleotide rather than small interfering RNA, and a six month primary endpoint versus 12 months for Novartis' trial.RBC said Dyne remains confident in its phase 3 study, with data expected in Q1 2027.Dyne is also running a confirmatory phase 3 study using the five times sit-to-stand test as its primary endpoint, providing a second opportunity to achieve statistical significance, the note said.The analysts also see a potential catalyst in Dyne's DMD51 program, with a US Food and Drug Administration decision expected Jan. 21, 2027.RBC maintained its outperform rating on Dyne Therapeutics and lower","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4578","PPH","LU0211331839.USD","LU0208291251.USD","IE0009355771.USD","IE00BFTCPJ56.SGD","NVS","BK4139","IE00B2B36J28.USD","DYN","IE00BJT1NW94.SGD","BK4505","BK4532","IE0002141913.USD","IE00BJJMRZ35.SGD","BK4585","LU0320765489.SGD","BK4007","BK4588","MEDX","LU0070302665.USD","IE00B4R5TH58.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666253906","title":"Novartis Shouldn't Rush to Cover Upcoming Patent Expirations","url":"https://stock-news.laohu8.com/highlight/detail?id=2666253906","media":"Dow Jones","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666253906?lang=en_us&edition=fundamental","pubTime":"2026-09-09 23:07","pubTimestamp":1788966420,"startTime":"0","endTime":"0","summary":"1507 GMT - Recent clinical-trial setbacks mean Novartis needs to be near-flawless in bringing the rest of its pipeline to the market or look for deals, but the Swiss drugmaker shouldn't rush it, RBC Capital Markets analysts say in a research note. \"Shares have pulled back from all-time highs, but we see no urgency to act,\" the analysts say. The failures of cardiovascular and neuromuscular drugs pelacarsen and del-desiran raise the bar for Novartis's pipeline, given that these were two important candidates to offset sales lost to upcoming patent expirations, they add. RBC starts coverage on the stock with a sector perform recommendation and a target price of 120 Swiss francs. Shares fall 0.3% to 111.44 francs.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","IE0002141913.USD","BK4588","MEDX","IE00B4R5TH58.HKD","BK4585","IE0009355771.USD","IE00B2B36J28.USD","LU0211331839.USD","LU0070302665.USD","PPH","NVS","BK4578","LU0208291251.USD","BK4532","IE00BJJMRZ35.SGD","LU0320765489.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666253912","title":"Tyra Biosciences Stock Plunges 22% as Bladder Cancer Pill Fails to Impress","url":"https://stock-news.laohu8.com/highlight/detail?id=2666253912","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666253912?lang=en_us&edition=fundamental","pubTime":"2026-09-09 22:44","pubTimestamp":1788965040,"startTime":"0","endTime":"0","summary":"Tyra Biosciences is taking on Johnson & Johnson to develop a next-generation treatment common type of bladder cancer, but the latest data for its experimental pill failed to inspire confidence.The Pha","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE000SO60NU8.SGD","LU0203347892.USD","LU1196500208.SGD","GDOC","LU2756315664.SGD","IHE","IE00B7SZLL34.SGD","IE000F7OJYX1.SGD","XLV","BK4532","JNJ","SG9999002232.USD","SG9999002224.SGD","FTXH","LU2468319806.SGD","LU1043141123.HKD","TRUH","IE00BLSP4239.USD","LU1291159041.SGD","LU0289739699.SGD","LU2430703178.SGD","BK4139","LU0426417589.USD","SGXZ80539844.SGD","LU1280957306.USD","LU1914381329.SGD","LU1551013342.USD","BK4550","LU2750360641.GBP","BMED","URGN","LU0203345920.USD","TYRA","IE000M9KFDE8.USD","LU2213496289.HKD","LU2403377893.USD","VHT","MEDX","LU0122379950.USD","IE00BFXG1179.USD","JDOC","PJP","IXJ","SGXZ57979304.SGD","LU1032466523.USD","RXL","LU1244550577.SGD","IYH","FHLC","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666539473","title":"Abbvie Exec Says Strong Balance Sheet and Long Growth Runway Allow Company to Consider Both Early- and Late-Stage Business Development Opportunities - Conf Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2666539473","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666539473?lang=en_us&edition=fundamental","pubTime":"2026-09-09 22:25","pubTimestamp":1788963943,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nFWN45113M:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00BLSP4452.SGD","TRUH","IE000MB6IJN5.SGD","FTXH","MEDX","IE00BLSP4239.USD","LU0234572021.USD","LU2089984988.USD","PPH","LU0289739699.SGD","LU2089284900.SGD","LU0170899867.USD","PJP","XLV","BK4566","LU0029864427.USD","LU2237443978.SGD","LU1934455277.USD","SG9999011175.SGD","LU0114720955.EUR","LU1236620834.HKD","LU1267930490.SGD","LU0158827948.USD","LU0708994859.HKD","LU0882574055.USD","IE00B19Z3B42.SGD","GLAM","LU1037948541.HKD","ABBV","IXJ","LU1989772840.SGD","SG9999015986.USD","JDOC","FHLC","VHT","LU0553294199.USD","LU0417517546.SGD","LU0289961442.SGD","LU0689626769.HKD","LU0912757837.SGD","IYH","RXL","LU1732799900.SGD","SG9999003800.SGD","LU2112291526.USD","AGNG","LU0122379950.USD","LU0965509010.AUD","LU0738911758.USD","LU0456855351.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666539343","title":"Abbvie Exec Says Expects Approval of Subcutaneous Crohn's Disease Treatment in Q4 - Conf Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2666539343","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666539343?lang=en_us&edition=fundamental","pubTime":"2026-09-09 22:25","pubTimestamp":1788963943,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nFWN45113M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00B19Z3581.USD","IE00B19Z3B42.SGD","LU1585245621.USD","LU1929549753.HKD","PPH","FTXH","LU2347655073.USD","IYH","LU0310799852.SGD","LU0198837287.USD","LU2125909593.SGD","BK4566","IE000BZT7R73.USD","IE0002270589.USD","IE00BDGV0183.EUR","IXJ","LU1236620834.HKD","LU1923622614.USD","TRUH","XLV","ABBV","LU0882574055.USD","JDOC","LU0122379950.USD","IE00BVYPNW00.USD","LU0128525929.USD","LU0472753341.HKD","LU1037948541.HKD","LU0820561818.USD","IE0000B7K699.USD","GLAM","IE00BLSP4452.SGD","LU2237443895.HKD","RXL","LU0098860793.USD","LU2129689431.USD","LU0689472784.USD","IE00BJJMRZ35.SGD","LU1003077747.HKD","VHT","PJP","MEDX","LU0965508806.USD","LU0726765562.USD","LU1093756325.SGD","AGNG","SG9999015986.USD","LU0912757837.SGD","FHLC","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107437767","title":"Henlius CEO Zhu Jun: Systematic Globalization Aims for Long-Term Gains, Innovative Drug Revenue Set to Surpass Biosimilars by 2030","url":"https://stock-news.laohu8.com/highlight/detail?id=1107437767","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107437767?lang=en_us&edition=fundamental","pubTime":"2026-09-09 21:11","pubTimestamp":1788959461,"startTime":"0","endTime":"0","summary":"During the 2026 Yabuli Forum Summer Annual Meeting, Henlius (02696.HK) Executive Director and CEO Dr. Zhu Jun outlined the company's \"systematic globalization\" strategy in an in-depth conversation,...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1992135399.USD","PPH","159992","BK4588","BK1161","LU1992135472.HKD","LNGR","LU2322448957.HKD","BK4585","LU2272731782.SGD","02696","LU2473716301.USD","HK0000320223.HKD","XPH","HK0000306685.HKD","HK0000165453.HKD","BK1574","HK0000320264.USD","06978","IBBQ","LU2322448791.USD","LU2272731865.HKD","MEDX","IE00B5TLWC47.USD","LU2272731600.USD","HK0000306701.USD","IBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666907533","title":"IMUNON Announces Full Agenda and Speaker Lineup Ahead of 2026 R&D Day Highlighting IMNN-001 Clinical Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2666907533","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666907533?lang=en_us&edition=fundamental","pubTime":"2026-09-09 20:30","pubTimestamp":1788957000,"startTime":"0","endTime":"0","summary":"Investors, media and stakeholders are invited to join in person in New York City or via live webcast on Wednesday, September 23, 2026, at 10:00 a.m. ET LAWRENCEVILLE, N.J., Sept.  09, 2026 (GLOBE NEWS","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/09/3358657/0/en/imunon-announces-full-agenda-and-speaker-lineup-ahead-of-2026-r-d-day-highlighting-imnn-001-clinical-progress.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVIB","LU2065732104.USD","PRGS","MEDX","GDOC","IMNN","BK4097","IDNA","HYLG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666538091","title":"ProQR Therapeutics doses first participant in AX-0811 clinical trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2666538091","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666538091?lang=en_us&edition=fundamental","pubTime":"2026-09-09 20:15","pubTimestamp":1788956125,"startTime":"0","endTime":"0","summary":"ProQR Therapeutics (PRQR) announced that the first participant has been dosed in the Phase 1 clinical trial of AX-0811 in healthy volunteers. Publi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/proqr-therapeutics-doses-first-participant-in-ax-0811-clinical-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/proqr-therapeutics-doses-first-participant-in-ax-0811-clinical-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","LU2360107671.USD","BK4139","AX","PRQR","LU1861217088.USD","MEDX","BK4539","GDOC","BK4195","IDNA","LU1861220207.SGD","NVIB","HYLG","BK4007","BK4211"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":15,"pageCount":3,"totalSize":298,"code":"91000000","status":"200"}]}}